| Oct 16 |
Zynex Sets Third Quarter 2024 Earnings Call
|
| Oct 9 |
Zynex, Inc.: 2025 Looks Like A Brighter Year
|
| Oct 9 |
Zynex price target lowered to $11 from $12 at RBC Capital
|
| Oct 3 |
Investors in Zynex (NASDAQ:ZYXI) have unfortunately lost 22% over the last five years
|
| Sep 6 |
In spite of recent selling, insiders still have the largest holding in Zynex, Inc. (NASDAQ:ZYXI) with a 51% ownership
|
| Sep 4 |
FDA clears Zynex’s TensWave device for pain management
|
| Sep 4 |
Zynex to Present at the HC Wainwright Global Investment Conference
|
| Sep 4 |
Zynex Stock Rises on FDA Clearance of Its New Pain Management Device
|
| Sep 3 |
Zynex wins FDA nod for new pain management device
|
| Sep 3 |
Zynex Obtains FDA clearance for new Pain Management Device
|
